Will PI3K Pathway Inhibitors Be Effective as Single Agents in Patients With Cancer?

Oncotarget - United States
doi 10.18632/oncotarget.409
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Correction: Will PI3K Pathway Inhibitors Be Effective as Single Agents in Patients With Cancer?

Oncotarget
Oncology
2018English

Drug Repositioning of Mevalonate Pathway Inhibitors as Antitumor Agents for Ovarian Cancer

Oncotarget
Oncology
2017English

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Cancer Therapeutics

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Inhibitors of the Fanconi Anaemia Pathway as Potential Antitumour Agents for Ovarian Cancer

2020English

Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Targeting the PI3K Signaling Pathway in Cancer

Current Opinion in Genetics and Development
GeneticsDevelopmental Biology
2010English

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment

Frontiers in Pharmacology
Pharmacology
2020English

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy